Furthermore, RSM3 serves as a stapled peptide inhibitor for METTL3 and can induce METTL3 degradation and suppress m6A mRNA methylation, exhibiting remarkable anticancer efficacy in a prostate cancer cell xenograft tumor model [264]. The gene discussed is METTL3; the disease is prostate carcinoma.